Investors Buy High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw unusually large options trading on Wednesday. Stock investors acquired 1,002 put options on the stock. This is an increase of 1,791% compared to the typical daily volume of 53 put options.

Maravai LifeSciences Price Performance

NASDAQ MRVI opened at $4.95 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences has a 1-year low of $4.28 and a 1-year high of $11.56. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -3.02 and a beta of -0.08. The business’s fifty day moving average price is $5.36 and its 200-day moving average price is $7.04.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.09) earnings per share (EPS) for the quarter. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The firm had revenue of $65.20 million for the quarter, compared to the consensus estimate of $67.58 million. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. On average, equities analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on MRVI shares. Guggenheim started coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating on the stock. Royal Bank of Canada decreased their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. The Goldman Sachs Group lowered shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $7.00 to $4.25 in a report on Thursday, December 5th. Finally, Robert W. Baird cut their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $10.28.

Insider Buying and Selling

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the transaction, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Carl Hull bought 175,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was bought at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the acquisition, the insider now directly owns 175,000 shares of the company’s stock, valued at approximately $987,000. This represents a ? increase in their position. The disclosure for this purchase can be found here. 0.63% of the stock is owned by insiders.

Institutional Trading of Maravai LifeSciences

Several large investors have recently added to or reduced their stakes in the business. Atria Investments Inc purchased a new position in shares of Maravai LifeSciences during the 4th quarter worth $58,000. Victory Capital Management Inc. raised its holdings in Maravai LifeSciences by 65.1% in the 4th quarter. Victory Capital Management Inc. now owns 96,273 shares of the company’s stock worth $525,000 after purchasing an additional 37,946 shares during the period. VELA Investment Management LLC lifted its position in Maravai LifeSciences by 54.5% during the fourth quarter. VELA Investment Management LLC now owns 148,112 shares of the company’s stock valued at $807,000 after purchasing an additional 52,246 shares in the last quarter. Y Intercept Hong Kong Ltd grew its holdings in Maravai LifeSciences by 155.9% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 32,359 shares of the company’s stock valued at $176,000 after purchasing an additional 19,713 shares during the period. Finally, Rhumbline Advisers increased its position in Maravai LifeSciences by 9.9% in the fourth quarter. Rhumbline Advisers now owns 185,221 shares of the company’s stock worth $1,009,000 after buying an additional 16,712 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.